Contralateral prophylactic mastectomy and survival: Report from the National Cancer Data Base, 1998-2002

Breast Cancer Research and Treatment

Volumn 142, Issue 3, 2013, Pages 465-476

  Yao, Katharine ^a   Winchester, David J ^a   Czechura, Tomasz ^a   Huo, Dezheng ^b  

^a NORTHSHORE UNIVERSITY HEALTHSYSTEM   (United States)

^b UNIVERSITY OF CHICAGO   (United States)

Author keywords

Bilateral mastectomy survival; Contralateral prophylactic mastectomy (CPM); Double mastectomy survival; National Cancer Data Base; Survival

Indexed keywords

ANTINEOPLASTIC AGENT;

ADULT; AGE; AGED; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER GRADING; CANCER HORMONE THERAPY; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; DATA BASE; FEMALE; FOLLOW UP; HEALTH CARE FACILITY; HEALTH INSURANCE; HISTOPATHOLOGY; HUMAN; MAJOR CLINICAL STUDY; MANAGED CARE; MASTECTOMY; MIDDLE AGED; MORTALITY; OVERALL SURVIVAL; PRIORITY JOURNAL; RACE; RADIOTHERAPY; REVIEW; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; DATABASES, FACTUAL; FEMALE; HUMANS; MASTECTOMY; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM STAGING; PROPORTIONAL HAZARDS MODELS; RISK FACTORS; YOUNG ADULT;

EID: 84890312421     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-013-2745-1     Document Type: Review

References (41)

1. Tuttle T, Havermann EB, Grund EH, Morris TJ, Virnig B (2007) Increasing use of contralateral prophylactic mastectomy for breast cancer patients: a trend toward more aggressive surgical treatment. J Clin Oncol 25(33):5203-5209
2. Tuttle T, Jarosek S, Habermann EB, Arrington A, Abraham A, Morris TJ, Virnig BA (2009) Increasing rates of contralateral prophylactic mastectomy among patients with ductal carcinoma in situ. J Clin Oncol 27(9):1362-1367
3. Yao K, Stewart A, Winchester DJ, Winchester DP (2010) Trends in contralateral prophylactic mastectomy for unilateral cancer: a report from the National Cancer Data Base, 1998-2007. Ann Surg Oncol 17:2554-2562
4. Katipamula R, Degnim AC, Hoskin T, Boughey JC, Loprinzi C, Grant CS, Brandt KR, et al. (2009) Trends in mastectomy rates at the Mayo Clinic Rochester: effect of surgical year and preoperative magnetic resonance imaging. J Clin Oncol 27(25):4082-4088
5. King TA, Sakr R, Patil S, et al. (2011) Clinical management factors contribute to the decision for contralateral prophylactic mastectomy. J Clin Oncol 29:2158-2164
6. Goldflam K, Hunt KK, Gershenwald JE, et al. (2004) Contralateral prophylactic mastectomy. Predictors of significant histologic findings. Cancer 101(9):1977-1986
7. Lee JSGC, Donohue JD, et al. (1995) Arguments against routine contralateral mastectomy or undirected biopsy for invasive lobular breast cancer. Surgery 118:640-648
8. Peralta EAEJ, Wagman LD, et al. (2000) Contralateral prophylactic mastectomy improves the outcome of selected patients undergoing mastectomy for breast cancer. Am J Surg 180:439-445
9. Herrinton LJBW, Yu O, Geiger AM, Elmore JG, Barton MB, Harris EL, et al. (2005) Efficacy of prophylactic mastectomy in women with unilateral breast cancer: a cancer research network project. J Clin Oncol 23(19):4275-4286
10. Bedrosian I, Hu CY, Chang GJ (2010) Population-based study of contralateral prophylactic mastectomy and survival outcomes of breast cancer patients. J Natl Cancer Inst 102:1-9
11. Boughey J, Hoskin TL, Degnim AC, et al. (2010) Contralateral prophylactic mastectomy is associated with a survival advantage in high risk women with a personal history of breast cancer. Ann Surg Oncol 17:2702-2709
12. Bilimoria K, Bentrem DJ, Winchester DP, Stewart AK, Ko CY (2009) Comparison of commission on cancer approved and non-approved hospitals in the United States: implications for studies that use the National Cancer Data Base. J Clin Oncol 27(25):4177-4181
13. Brewster A, Bedrosian I, Parker PA, Dong W, et al. (2012) Association between contralateral prophylactic mastectomy and breast cancer outcomes by hormone receptor status. Cancer 118(22):5637-5643
14. Lostumbo L, Carbine N, Wallace J, et al. (2004) Prophylactic mastectomy for the prevention of breast cancer. Cochrane Database Syst Rev 4:CD002748
15. Bilimoria K, Bentrem DJ, Winchester DP, Stewart AK, Ko CY (2008) The National Cancer Data Base: a powerful initiative to improve cancer care in America. Ann Surg Oncol 15(3):683-690
16. U.S. Census Bureau USC (2000). http://www.census.gov/main/www/cen2000. html. Accessed 15 April 2013
17. Greene FL (2002) AJCC cancer staging manual. Springer-Verlag, New York
18. Chung A, Huynh K, Lawrence C, Sims MS, Giuliano A, et al. (2012) Comparison of patient characteristics and outcomes of contralateral prophylactic mastectomy and unilateral total mastectomy in breast cancer patients. Ann Surg Oncol 19(8):2600-2606
19. Babiera G, Lowy AM, Davidson BS, Singletary SE (2007) The role of contralateral prophylactic mastectomy in invasive lobular carcinoma. Breast J 3(1):2-6
20. Tuttle T, Habermann EB, Virnig B (2010) Re: population-based study of contralateral prophylactic mastectomy and survival outcomes of breast cancer patients. J Natl Caner Inst 102(17):1371-1372
21. Fisher BAS, Bryant J, Margolese RG, Deutsch M, Fisher ER, Jeong JH, et al. (2002) Twenty year follow up of a randomized trial comparing total mastectomy, lumpectomy and lumpectomy plus irradiation for the treatment of invasive breast cancer. N Engl J Med 347:1233-1241
22. Gao X, Fisher SG, Emami B (2003) Risk of second primary cancer in the contralateral breast in women treated for early-stage breast cancer: a population-based study. Int J Radiat Oncol Biol Phys 56(4):1038-1045
23. Fisher B, Jeong JH, Bryant J, Anderson S, et al. (2004) Treatment of lymph-node-negative, oestrogen-receptor-positive breast cancer: long-term findings from national surgical adjuvant breast and bowel project randomised clinical trials. Lancet 4(364):858-868
24. Fisher B, Land S, Mamounas E, et al. (2001) Prevention of invasive breast cancer in women with ductal carcinoma in situ: an update of the national surgical adjuvant breast and bowel project experience. Semin Oncol 28(4):400-418
25. Cuzick J, Sestak I, Baum M, Buzdar A, et al. (2010) Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial. Lancet Oncol 11(12):1135-1141
26. Early Breast Cancer Trialists' Collaborative Group (1998) Polychemotherapy for early breast cancer: an overview of the randomized trials. Lancet 352:930-942
27. Houssami N, Ciatto S, Martinelli F, Bonardi R, Duffy SW (2009) Early detection of second breast cancers improves prognosis in breast cancer survivors. Ann Oncol 9:1505-1520
28. Narod SA (2011) The impact of contralateral mastectomy on mortality in BRCA1 and BRCA2 mutation carriers with breast cancer. Breast Cancer Res Treat 128:581-583
29. Bernstein J, Lapinski RH, Thakore SS, Doucette JT, Thompson WD (2003) The descriptive epidemiology of second primary breast cancer. Epidemiology 14(5):552-558
30. Reiner A, John EM, Brooks JD, Lynch CF, Bernstein L, Mellemkjaer L, Malone KE, Knight JA, Capanu M, Teraoka SN, Concannon P, Liang X, Figueiredo JC, Smith SA, Stovall M, Pike MC, Haile RW, Thomas DC, Begg CB, Bernstein JL (2010) Risk of asynchronous contralateral breast cancer in noncarriers of BRCA1 and BRCA2 mutations with a family history of breast cancer: a report from the women's environmental cancer and radiation epidemiology study. J Clin Oncol 31:433-439
31. Rhiem K, Engel C, Graeser M, et al. (2012) The risk of contralateral breast cancer in patients from BRCA1/2 negative high risk families as compared to patients from BRCA1 or BRCA2 positive families: a retrospective cohort study. Breast Cancer Res 14:R156
32. Pierce L, Levin AM, Rebbeck TR, et al. (2006) Ten-year multi-institutional results of breast-conserving surgery and radiotherapy in BRCA1/2-associated stage I/II breast cancer. J Clin Oncol 24(16):2437-2443
33. Mavaddat N, Barrowdale D, Andrulis IL, et al. (2012) Pathology of breast and ovarian cancer among BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1/2. Cancer Epidemiol Biomarkers Prev 21(1):134-147
34. Chen S, Parmigiani G (2007) Meta-analysis of BRCA1 and BRCA2 penetrance. J Clin Oncol 25(11):1329-1333
35. Rebbeck TF, Lynch HT, et al. (2004) Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group. J Clin Oncol 22(6):1055-1062
36. Heemskerk-Gerritsen B, Menke-Pluymers MBE, et al. (2007) Prophylactic mastectomy in BRCA 1/2 mutation carriers and women at risk of hereditary breast cancer: long-term experiences at the Rotterdam Family Cancer Clinic. Ann Surg Oncol 14(12):3335-3344
37. Hartman L, Woods JE (1999) Efficacy of bilateral prophylactic mastectomy in women with a family history of breast cancer. N Engl J Med 340:77-84
38. Robinson E, Rennert G, Rennert HS, et al. (2006) Survival of first and second primary breast cancer. Cancer 71(1):172-176
39. Schaapveld M, Visser O, Louwman WJ, et al. (2008) The impact of adjuvant therapy on contralateral breast cancer risk and the prognostic significance of contralateral breast cancer: a population based study in the Netherlands. Breast Cancer Res Treat 110(1):189-197
40. Hartman M, Czene K, Reilly M, Adolfsson J, et al. (2007) Incidence and prognosis of synchronous and metachronous bilateral breast cancer. J Clin Oncol 25:4210-4216
41. Vichapat V, Garmo H, Holmqvist M, et al. (2012) Tumor stage affects risk and prognosis of contralateral breast cancer: results from a large Swedish-population-based study. J Clin Oncol 30:3478-3485